Phase 1/2Completed
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
A Randomized, Single-Blind, Endoscopic Evaluation Of Upper GI Mucosal Damage Induced By PL-2200 Versus Aspirin In Healthy Volunteers
- Sponsor
- PLx Pharma (Industry)
- Enrolment
- 204 enrolled
- Conditions
- Upper Gastrointestinal Mucosal Damage
- Interventions
- acetylsalicylic acid
- Ages
- adults, older adults
- Registry
- NCT00872534
Full record on ClinicalTrials.gov
From the registry
To determine the gastrointestinal safety of PL-2200 versus immediate-release aspirin by assessing endoscopic gastroduodenal mucosal injury at approved daily cardiac-protective doses of aspirin (325 mg) in normal healthy volunteers.
Primary outcomes
- Incidence of Subjects With Gastroduodenal Erosions and Ulcers.
History
Results first posted
Last registry update
Primary completion
Registered
Started